Home Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer
Article
Licensed
Unlicensed Requires Authentication

Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer

  • Muqtader Mohammed EMAIL logo , Mansour S. Alnafisah , Md. Khalid Anwer EMAIL logo , Farhat Fatima , Bjad K. Almutairy , Saad M. Alshahrani , Abdullah S. Alshetaili , Ahmed Alalaiwe , Mohamed H. Fayed , Ahmad Z. Alanazi , Mohammed Al Zahrani , Mohammad M. Hailat and Ramadan Al-Shdefat
Published/Copyright: October 22, 2019
Become an author with De Gruyter Brill

Abstract

In the current study, surface-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of brigatinib (BRB) were prepared by studying the variables PLGA (polymer), PVA (stabilizer) and chitosan (coater) against experimentally obtained responses. The optimized NPs (F2) were evaluated in vitro for differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), particle size, polydispersity index (PDI) and drug entrapment (EE), in vitro release, hematocompatibility and in vitro anticancer studies. The optimized NPs’ (F2) composition, PLGA (75 mg), PVA (0.55% w/v), chitosan (0.75% w/v) and 30 mg of BRB was found to be optimum with particle size (406.3 ± 5.1 nm), PDI (0.277), ζ potential (30.4 ± 3.3 mV) and %EE (82.32%). The in vitro release profile showed a sustained release pattern of the F2 nanoparticles of BRB. The 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay revealed a significant anticancer activity for F2 NPs against A549 cell lines in comparison to free BRB. The result obtained in this work indicated the immense potential of nanoparticles to effectively deliver the BRB to the cancer site for the treatment of non-small cell lung cancer.

Acknowledgements

This project was supported by the Deanship of Scientific Research at Prince Sattam Bin Abdulaziz University under the research project no. 2019/03/10912.

  1. Conflict of interest statement: The authors declare no conflict of interests associated with this study.

References

[1] Approved Drugs – Brigatinib. 2017. Retrieved from https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm. Accesssed 25 July, 2017.Search in Google Scholar

[2] Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y. Front. Oncol. 2019, 8, 557.10.3389/fonc.2018.00557Search in Google Scholar PubMed PubMed Central

[3] Zhao P, Peng L, Wu W, Zheng Y, Jiang W, Zhang H, Tong Z, Liu L, Ma R, Wang L, Yao M, Wang K, Fang W, Wu L. Oncologist 2018, ii, 2018–2439.Search in Google Scholar

[4] Alberg A, Nonemaker J. Semin. Respir. Crit. Care Med. 2008, 29, 223–232.10.1055/s-2008-1076742Search in Google Scholar PubMed PubMed Central

[5] Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ. Ann. Oncol. 2015, 26, 902–907.10.1093/annonc/mdv061Search in Google Scholar PubMed

[6] Chs.gov.sa. 2018. http://www.chs.gov.sa/Ar/HealthCenters/NCC/CancerRegistry/CancerRegistryReports/2013.pdf.Search in Google Scholar

[7] Cancer.org. Key statistics for lung cancer. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html.Search in Google Scholar

[8] Cheikh A, Majjaoui S, Ismaili N, Cheikh Z, Bouajaj J, Nejjari C, Hassani A, Cherrah Y, Benjaafar N. Rabat. The Pan. Afr. Med. J. 2016, 23, 209.10.11604/pamj.2016.23.209.7750Search in Google Scholar

[9] Highlights of prescribing information. ALUNBRIG® (brigatinib) tablets, for oral use initial U.S. approval: 2017. FVG. https://www.alunbrig.com/assets/pi.pdf.Search in Google Scholar

[10] Gentile P, Chiono V, Carmagnola I, Hatton P. Int. J. Mol. Sci. 2014, 15, 3640–3659.10.3390/ijms15033640Search in Google Scholar PubMed PubMed Central

[11] Mir M, Ahmed N, Rehman AU. Colloids Surf. B Biointerf. 2017, 159, 217–231.10.1016/j.colsurfb.2017.07.038Search in Google Scholar PubMed

[12] Anwer MK, Mohammad M, Ezzeldin E, Fatima F, Alalaiwe A, Iqbal M. Int. J. Nanomed. 2019, 14, 1587–1595.10.2147/IJN.S195048Search in Google Scholar PubMed PubMed Central

[13] Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. Pharmaceutics 2017, ii, E53.10.3390/pharmaceutics9040053Search in Google Scholar PubMed PubMed Central

[14] Pandit J, Sultana Y, Aqil M. Artif. Cells Nanomed. Biotechnol. 2016, 45, 1397–1407.10.1080/21691401.2016.1243545Search in Google Scholar PubMed

[15] Dina R and Hans-Georg S. Microb. Biotechnol. 2009, 2, 186–201.10.1111/j.1751-7915.2008.00080.xSearch in Google Scholar PubMed PubMed Central

[16] Aranaz I, Panos I, Peniche C, Heras A, Acosta N. Molecules 2017, 22, E1980.10.3390/molecules22111980Search in Google Scholar PubMed PubMed Central

[17] Lu B, Lv X, Le Y. Polymers 2019, 11, 2–14.10.3390/polym12010002Search in Google Scholar

[18] De Jong WH, Borm PJ. Int. J. Nanomed. 2008, 3, 133–149.10.2147/IJN.S596Search in Google Scholar

[19] Jorquera P, Tripp R. Vaccines 2016, 4, pii. E45.10.3390/vaccines4040045Search in Google Scholar

[20] Shen S, Wu Y, Liu Y, Wu D. Int. J. Nanomed. 2017, 12, 4085–4109.10.2147/IJN.S132780Search in Google Scholar

[21] Singh S, Verma D, Mirza MA, Das AK, Dudeja M, Anwer MK, Sultana Y, Talegaonkar S, Iqbal Z. J. Drug Deliv. Sci. Technol. 2017, 39, 95–103.10.1016/j.jddst.2017.03.007Search in Google Scholar

[22] Anwer MK, Al-Shdefat R, Ezzeldin E, Alshahrani SM, Alshetaili AS, Iqbal M. Front. Pharmacol. 2017, 8, 844.10.3389/fphar.2017.00844Search in Google Scholar

[23] Anwer MK, Al-Mansoor MA, Jamil S, Al-Shdefat R, Ansari MN, Shakeel F. Int. J. Biol. Macromol. 2016, 92, 213–219.10.1016/j.ijbiomac.2016.07.002Search in Google Scholar

[24] Alshahrani SM, Mohammad M, Anwer MK, Fatima F, Alshetaili AS, Alalaiwe A, Alsulays BB, Shakeel F. Acta Pol. Pharm. 2019, 76, 225–232.10.32383/appdr/94616Search in Google Scholar

[25] Choi J, Reipa V, Hitchins VM, Goering PL, Malinauskas RA. Toxicol. Sci. 2011, 123, 133–143.10.1093/toxsci/kfr149Search in Google Scholar

[26] Bahuguna A, Khan I, Bajpai VK, Kang SC. Bangladesh J. Pharmacol. 2017, 12, 115–118.10.3329/bjp.v12i2.30892Search in Google Scholar

[27] Mosmann T. J. Immunol. Methods 1983, 65, 55–63.10.1016/0022-1759(83)90303-4Search in Google Scholar

[28] Rozamus LW, Sharma P. Singapura Patent No. 11201702980Q A1. 2017.Search in Google Scholar

[29] Alshetaili AS, Anwer MK, Alshahrani SM, Alalaiwe A, Alsulays BB, Ansari MJ, Imam F, Alsheri S. Trop. J. Pharm. Res. 2018, 17, 1263–1269.10.4314/tjpr.v17i7.6Search in Google Scholar

[30] Anwer MK, Jamil S, Ansari MJ, Iqbal M, Imam F, Shakeel F. Mat. Res. Innov. 2016, 20, 193–197.10.1179/1433075X15Y.0000000049Search in Google Scholar

[31] Bohrey S, Chaurasiya V, Pandey A. Nano. Converg. 2016, 3, 2–7.10.1186/s40580-016-0065-ySearch in Google Scholar PubMed PubMed Central

Received: 2019-08-09
Accepted: 2019-09-04
Published Online: 2019-10-22
Published in Print: 2019-11-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 10.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/polyeng-2019-0265/html
Scroll to top button